Cytokine gene polymorphisms predict acute graft rejection of histocompatibility matching and improved immunofollowing renal transplantation.
frequency and severity of acute rejection episodes (REs) acute rejection, while animal models suggest a role for interleumay be a predisposing factor in reduced renal function kin-10 (IL-10) in promoting graft survival. It has also been shown that polymorphisms in the TNFA gene promoter (posi- and subsequent graft loss [1] [2] [3] . an array of cytokines that promote various mechanisms
Results. The recipient TNF-␣ high producer genotype and involved in allograft rejection. Cytokines can be catego-IL-10 high producer genotype were significantly associated with rized into two broad groups [5] . The so-called Th1-type multiple REs (Ն2) in human leukocyte antigen (HLA)-DR miscytokines, including interleukin-2 (IL-2), tumor necrosis matched transplants (P ϭ 0.0047 and P ϭ 0.045, respectively), whereas only the TNF-␣ high producer genotype was associfactor-␣ (TNF-␣), TNF-␤, and interferon-␥ (IFN-␥), meated with steroid-resistant REs (P ϭ 0.025). When recipient diate cellular immune responses and are proinflammacytokines were analyzed together, the TNF-␣ high/IL-10 high tory. Second, cytokines described as the Th2 type, which producer genotype had the worst prognosis, whereas TNF-␣ include IL-4, IL-5, and IL-10, have been shown to inhibit low/IL-10 low producer genotype was protective.
the development and function of Th1 cells, suppress in- lates macrophage function and increases MHC class II antigen expression, has been implicated in acute rejecAlthough the one-year survival rate for cadaveric retion [6] and chronic rejection [7] . The activation of endonal transplants has increased with greater understanding thelial cells and the subsequent expression of the intercellular adhesion molecule-1 (ICAM-1) induced by TNF-␣ can enhance vascular permeability and therefore rejection in kidney transplants [9] . Conversely, IL-10 has the ability to inhibit APC function, TNF-␣ production
[10], and ICAM-1 expression in vitro [11] . Evidence from reduced depending on blood levels. Transplant patients with delayed graft function were commenced on a triple animal transplant models has suggested a role for the immunoregulatory cytokine IL-10 in promoting graft therapy regimen of CsA, prednisolone, and azathioprine. Out of the 115 patients considered initially, 15 were survival [12] . However, others have provided evidence supporting the role of IL-10 in rejection [13] [14] [15] .
subsequently excluded from the study: 4 with allograft vessel thrombosis or other surgical problems resulting The level of production of these cytokines at the site of the allograft could be important in accelerating or in early loss of the graft, 1 because of nonadherence with the drug regimen, 4 because they lost their grafts to suppressing rejection. The level of cytokine production has been associated with polymorphisms in cytokine causes other than rejection in the first three months, and in 6 because either records were missing or they had gene promoters [16, 17] . Promoter region polymorphisms, it is postulated, may directly or indirectly affect been transferred to other centers for follow-up. Matching data for the remaining 100 patients showed that 74 out the binding of transcription factors and might consequently increase or decrease the production of mRNA, of 100, 75 out of 100, and 40 out of 100 had mismatches at the HLA-A, -B, and -DR loci, respectively. Only 1 of thus regulating cytokine production. It has been shown that a G to A polymorphism at position Ϫ308 on the the 40 HLA-DR-mismatched transplants had two mismatches. Female recipients made up 29% of all recipi-TNFA gene promoter, giving alleles TNF1 and TNF2, respectively, is associated with a sixfold to sevenfold ents. Post-transplant patients were followed up regularly in the transplant clinic, and relevant data were collected. increase in transcription of the TNF-␣ gene in vitro [18, 19] . Furthermore, it has been demonstrated that this We were able to analyze only 88 corresponding donors because of the availability of donor DNA samples. polymorphism determines TNF-␣ production in vitro [20] . We have previously shown that a G to A polymorControl DNA samples phism (alleles IL-10 1*G and IL-10 1*A, respectively) at position Ϫ1082 in the IL-10 gene promoter correlates Frequencies for TNF-␣ and IL-10 alleles in nontransplant recipients were determined from laboratory staff with lower IL-10 production in stimulated lymphocytes in vitro [17] .
and cadaveric kidney transplant donors from a different cohort. Having established the relationship between cytokine production and cytokine gene polymorphism, a simple Rejection episodes and severity polymerase chain reaction (PCR)-based screening technique was developed and used to genotype renal transRejection episodes were defined by clinical diagnosis (elevated serum creatinine in the absence of other paplant recipients and their donors. This was performed to determine the influence of these gene polymorphisms thology, including infection, urinary tract obstruction, allograft artery stenosis, or CsA toxicity) and were conon renal allograft REs and severity (RS) in the first six months following renal transplantation and on chronic firmed by a positive biopsy where possible. All biopsies were reviewed by a single renal pathologist (I.S.D.R.), transplant nephropathy (CTN) and subsequent graft survival. Polymorphisms of the TNF-␣ and IL-10 gene proand the Banff 93 working classification criteria were used in the histological classification of the biopsies [22] . A moters were analyzed in 115 consecutive first cadaveric renal patients transplanted between February 1990 and clinically suspected episode of acute rejection was usually confirmed with a biopsy of the allograft and was treated January 1991 at our center and who have a minimum follow-up of five years.
with three consecutive intravenous daily doses of 1 g methylprednisolone and was further classified according to severity, namely steroid-responsive or steroid-resis-METHODS tant acute rejection. Steroid-resistant rejection or a third Patients and donors episode of rejection was usually treated with anti-thymocyte globulin (ATG). Steroid-responsive acute rejections One hundred and fifteen consecutive recipients of first cadaveric renal transplants engrafted at a single unit were rejections with creatinine levels returning to within 10% of prerejection levels after a pulse of steroid. Conbetween February 1990 and January 1991 were selected for the study. Recipients were allocated kidneys as preversely, REs were considered steroid resistant when creatinine levels remained 10% above that of prerejection viously described [21] . Selection for transplantation was based on ABO blood group compatibility, a negative levels after a pulse of steroid and/or required ATG/ OKT3 treatment. Biopsy confirmation of rejection was complement-dependent cytotoxicity cross-match using all historic positive and current sera, and the best HLA obtained in 23 out of 69 (33%) steroid-responsive rejections and 7 out of 9 (78%) of steroid-resistant rejections. match with no more than three HLA-A, -B and -DR antigen mismatches. All patients with primary function Similarly, 10 out of 33 (30%) of steroid responsive rejections and 4 out of 5 (80%) of steroid-resistant rejections were given cyclosporine A (CsA) monotherapy at an initial dose of 15 mg/kg/day. The dosage was gradually were histologically confirmed in patients with HLA-DR-mismatched transplants. The RE and the RS values were IL-10 high/low production frequencies between patient and control groups were analyzed by the Fisher's exact then correlated with patients' cytokine genotypes (high or low producers). The influence of the cytokine genotest for 2 ϫ 2 tables (Epi Info 6; CDC, Atlanta, GA, USA). Results are presented as relative risk (RR), with type on the REs and the RS was assessed for the first six-months post-transplant. To study the effect of cyto-95% confidence intervals (CI). Patients with the high or low cytokine producer genotypes were further divided kine gene polymorphism on RS, only the most severe episode for each individual was used. Patients who died into two groups in terms of REs: those who had less than 1 or no REs (Յ1) and those who had multiple RE with functioning grafts or underwent transplant nephrectomy because of nonimmunological complications within (Ն2). The influence of HLA-A, -B, and -DR matching and the influence of cytokine genotype on the REs and this period were therefore excluded from these analyses (N ϭ 5).
RS were analyzed using the Fisher's exact test for 2 ϫ 2 tables unless otherwise stated. Similarly, the effect of Chronic transplant nephropathy cytokine gene polymorphism on CTN and graft survival was analyzed. A two-tailed P value of less than 0.05 was Chronic transplant nephropathy was defined clinically as a gradual deterioration of allograft function with a taken to be statistically significant, as well as a P of less than 0.10 as a trend. mean rise in yearly serum creatinine levels of over 15% (in the absence of infection, urinary tract obstruction, allograft artery stenosis, or CsA toxicity). Nine recipients RESULTS in this cohort had CTN, of which 6 (66%) were also Cytokine production genotype frequencies confirmed with biopsy.
In the renal transplant group, 80 out of 100 (80%) of Long-term graft survival patients had the low IL-10 producer genotypes (IL-10 1*G/IL-10 1*A and IL10 1*A/IL-10 1*A) compared with The effect of the polymorphisms on five-year graft survival was also assessed. Patients who died with func-75 out of 119 (63%) of the same genotypes in controls (P ϭ 0.08). The TNF-␣ high producer genotype (TNF2/ tioning grafts or who lost their grafts because of nonimmunological reasons were excluded from this analysis.
TNF2, TNF2/TNF1) and the TNF-␣ low producer genotype (TNF1/TNF1) frequencies were similar in both DNA extraction groups. We also assessed the influence of cytokine gene polymorphisms on original disease but found no signifiGenomic DNA from whole blood or frozen cells was obtained by phenol extraction and ethanol precipitation cant association, perhaps because of the low numbers in each category. following proteinase K (Boehringer Mannheim, Mannheim, Germany) digestion.
Effect of human leukocyte antigen-A, -B, and -DR mismatch on rejection episodes Cytokine promoter region polymorphism analysis
The TNFA promoter polymorphism at position Ϫ308 Mismatches in both HLA-A, -B, and -DR did not influence REs and RS in the first six-months post-transwas analyzed by PCR-restriction fragment length polymorphism (PCR-RFLP) as previously described (abplant. However, there was a significantly greater proportion of recipients with HLA-DR-mismatched transstract; Wilson et al, Human Mol Genet 1:353, 1992). Individuals with the rarer allele TNF2 (including both plants with multiple REs as compared with those with zero mismatches when only early REs up to threehomozygotes and heterozygotes) were considered TNF-␣ high producers. IL-10 promoter gene polymorphism was months post-transplantation were considered (12 out of 40 with HLA-DR-mismatched transplants had multiple analyzed using sequence-specific oligonucleotide probes (SSOP) as previously described by Turner et al [17] . The RE as compared with only 7 out of 60 with matched transplants, P ϭ 0.042, Yates analysis). biotinylated oligonucleotide probes were designed to detect polymorphism in a dot blot technique. Individuals
Cytokine gene polymorphisms and rejection episodes who were IL-10 1*A positive (including both homozygotes and heterozygotes) were classified as IL-10 low Recipients and donors were grouped into high or low cytokine producer genotypes, and these data were correproducers according to previously defined criteria [17] . The technical aspects of genotyping have been described lated with REs (Table 1) . When all patients were analyzed independently of HLA-DR matching, no associain detail [23] .
tion was found between cytokine gene polymorphism Statistical analysis and REs. However, the recipient TNF-␣ high producer genotype (TNF2 positive) showed an association with Patients were grouped into the predicted high or low producer phenotypes according to their genotypes as increased REs only when the HLA-DR-mismatched transplants were analyzed separately. A greater propordefined previously [16, 17, 23]. Differences in TNF-␣ and tion of the recipients with TNF-␣ high producer genotype genotypes (10 out of 17, 59%, P ϭ 0.003, RR ϭ 0.16, 95% CI, 0.04 to 0.64, Yates analysis). However, no assohad multiple REs (7 out of 10, 70%) compared with recipients with the TNF-␣ low producer (TNF2 negative) ciations were found with the presence or absence of REs and the recipient TNF-␣ high/IL-10 high producer genotype (5 out of 28, 18%, P ϭ 0.0047, RR ϭ 3.92, genotype (TNF2 positive/IL-10 1*A negative). 95% CI, 1.61 to 9.57). Similarly, a greater proportion of recipients with IL-10 high producer genotype (IL-10 1*A Cytokine gene polymorphism and rejection severity negative) had multiple REs (6 out of 10, 60%) as comWhen the effect of cytokine gene polymorphisms on pared with only 6 out of 28 (21%) recipients with the RS was analyzed, only the recipient TNF-␣ high pro-IL-10 low producer genotype (IL-10 1*A positive; P ϭ ducer genotype (TNF2 positive) was associated with in-0.045, RR ϭ 2.80, 95% CI, 1.17 to 6.69). Furthermore, creased RS (Table 3) . Seven out of 21 (33%) recipients when the recipients were classified according to the preswith the TNF-␣ high producer genotype had steroidence or absence of REs, the recipient TNF-␣ high proresistant rejections compared with 2 out of 29 (7%) recipducer genotype, but not the IL-10 high producer genoients with the TNF-␣ low producer genotype (TNF2 negtype, was associated with an increase in the incidence of ative, P ϭ 0.025, RR ϭ 4.83, 95% CI, 1.11 to 20.97). REs in HLA-DR-mismatched transplants. Nine out of Five out of the seven steroid-resistant rejections in the 10 (90%) of the recipients with the TNF-␣ high producer recipients with the TNF-␣ high producer genotype were genotype (TNF2 positive) had one or more REs combiopsy confirmed rejections: one was Banff grade 4 (III), pared with 13 out of 28 (46%) of recipients with the two were grade 4 (IIb), and the remaining two were TNF-␣ low producer genotype (TNF2 negative, P ϭ grade 4 (IIa) and 4 (I) rejections. Although the IL-10 0.06). No associations with multiple REs were found high producer genotype (IL-10 1*A negative) was not when donor TNF-␣ and IL-10 genotypes were analyzed significantly correlated to steroid-resistant rejections, (Table 1) .
there was a positive trend linking the IL-10 high producer Cytokine gene polymorphism profile and genotype to steroid-resistant rejections (P ϭ 0.065, RR ϭ rejection episodes 3.20, 95% CI, 1.05 to 9.78). Out of the four steroidresistant rejections in the IL-10 high producer group, To assess the combined effect of cytokine polymoronly two had biopsy confirmation, and both were graded phism combinations in relation to REs, we analyzed data 4 (I). No associations with RS were found when donor for both TNF-␣ and IL-10 together for individual recipi-TNF-␣ and IL-10 genotypes were analyzed (Table 3) . ents. Only HLA-DR-mismatched transplants were analyzed because we have shown that only mismatching at Cytokine gene polymorphism profile and this locus increases REs in recipients with TNF-␣ and rejection severity IL-10 in this cohort (Table 1) . A greater proportion of recipients with the TNF-␣ high/IL-10 high producer
To assess the combined effect of cytokine gene polymorphism in relation to RS, we analyzed data for both genotype (TNF2 positive/IL-10 1*A negative) had multiple REs (3 out of 3, 100%) as compared with 9 out of TNF-␣ and IL-10 together for individual patients (Table  4) . A greater proportion of recipients with the TNF-␣ 35 (26%) with all other genotypes (P ϭ 0.026, RR ϭ 3.89; 95% CI, 2.21 to 6.83; Table 2 a Significantly more patients with the TNF-a high/IL-10 high producer genotype had muliple RE (3/3, 100%) as compared to 9/35 (26%) with all other genotypes (P ϭ 0.026, RR ϭ 3.89, 95% CI 2. 21-6.83) b Significantly fewer patients with the TNF-a low/IL-10 low producer genotype had multiple RE (2/21, 8%) as compared to 10/17 (59%) with all other genotypes, (P Ͻ 0.003, RR ϭ 0.16, 95% CI 0.04-0.064) Cytokines have been implicated in the regulation of steroid-resistant rejections (1 out of 23, 4%) as compared acute rejection. In this study, we investigated the role of with all other genotypes (8 out of 27, 30%, P ϭ 0.028, recipient and donor cytokine gene polymorphism on RR ϭ 0.15, 95% CI, 0.02 to 1.09).
REs and RS. These gene polymorphisms have been Effect of cytokine genotype on chronic transplant shown to influence interindividual production of the renephropathy and long-term graft survival spective cytokines in vitro. The interindividual differences in cytokine production have the potential to influAt five-years post-transplant, 9 out of 100 patients had lost their grafts through chronic rejection. There was no ence the various immune and inflammatory responses within the graft. This difference in cytokine production release in patients with the TNF2-positive genotype who also received a HLA-DR-mismatched transplant. Furbetween individuals is expected to be exacerbated in the presence of HLA-A, -B, or -DR mismatching. Although thermore, the recipient TNF-␣ high producer genotype was associated with steroid-resistant REs (Table 3) . this study could not demonstrate that HLA-A, -B, and -DR matched transplants had significantly fewer REs or When the high IL-10 production genotype was analyzed in all the patients, it was not associated with REs. less severe rejections in the first six months following transplantation, we observed a trend indicating a protecHowever, in recipients with HLA-DR-mismatched transplants, the IL-10 high producer genotype was assotive effect of HLA-DR matching in REs in the first three months following renal transplantation compared with ciated with an increase in the incidence of multiple REs (Table 1) . This association was weaker than that of mismatched transplants. This is not unusual and supports other studies with similar observations [24] . The CD4ϩ TNF-␣. This correlation was surprising considering the anti-inflammatory functions of IL-10. We had expected Th cells are activated directly via donor alloantigens associated with the HLA molecules expressed on the that the high IL-10 production would act against the production of the proinflammatory Th1-type cytokines graft. Therefore, matching at the HLA-DR locus would reduce Th-cell activation and alloantigen recognition.
such as TNF-␣ and hence suppress acute graft rejection. However, recent reports have suggested that IL-10 may The smaller number of REs might be attributed to the down-regulation of Th-cell effector functions and cytoenhance antibody responses against the graft [13] and low IL-10 responses can be used to predict a low risk kine release.
The analysis of the high/low cytokine producer genofor acute graft rejection [14] . Furthermore, IL-10 is a potent stimulator, inducing differentiation and proliferatype frequencies showed that the frequency of the IL-10 low producer genotype in renal recipients was higher tion of B cells, thus driving the immune response toward the humoral pathway [27] . when compared with normal controls. Even though this difference was only approaching statistical significance, Previously, our laboratory has documented in heart transplant recipients that a certain combination of it may suggest that the IL-10 high producer genotype could have a protective effect against certain of the origi-TNF-␣ and IL-10 gene polymorphisms (the TNF-␣ high/ IL-10 low group) was associated with higher levels of nal diseases progressing to end-stage renal failure. This finding fits in well with the observation that in vitro rejection [28] . This underlines the complex nature of allograft rejection and emphasizes the importance of studypretransplant B-cell responses in patients with end-stage renal disease were significantly lower compared with ing the role of a cytokine in the context of others. Therefore, to determine the combined effect of TNF-␣ and healthy controls [14] because IL-10 is essential for B-cell growth and development.
IL-10 genotypes on REs and RS in renal transplant patients, we categorized the patients into the four possible When recipient TNF-␣ gene polymorphisms were analyzed individually in all recipients, we did not find any genotype combinations and correlated these with the REs (Tables 2 and 4) . We found the TNF-␣ high/IL-10 relationship between the genotypes and the incidence of multiple REs (Table 1) . This result could be explained by high producer genotype to give a strong association with the incidence of multiple REs in HLA-DR-mismatched the effect of high-dose CsA immunosuppressive therapy during the early post-transplant period. The action of transplants and with steroid-resistant REs. Contrary to previous studies, which indicated a protective role of CsA in inhibiting the production and release of the proinflammatory Th1 cytokines is well documented [25] . The IL-10 in transplant rejection [12, 29] , we found that the IL-10 high producer genotype did not protect against transcription of the TNF-␣ gene, which requires the translocation of the cytoplasmic nuclear factor of activathe influence of the TNF-␣ high producer genotype. A recipient TNF-␣ high/IL-10 high producer genotype may tion of T cells, may be inhibited by CsA [25] . Alternatively, the effect of the TNF-␣ high producer genotype influence REs by the up-regulation of both the cellular and humoral responses. Why this genotype combination might have been masked when we analyzed all of the patients together independently of HLA-DR matching is associated with rejection in kidney but not in heart transplants is uncertain. One reason may be because of status. This explanation is more plausible because 60% of our transplants were matched at the HLA-DR locus.
an organ to organ variation that may affect the microenvironment in which the cytokines exert their influence. Furthermore, in patients with highly allogeneic HLA-DR-mismatched transplants, the TNF-␣ high producer
Another reason may be the use of a different immunosuppressive regimen for patients receiving heart transgenotype was linked with the presence of REs and was strongly associated with an increase in the incidence of plants (triple therapy of CsA, prednisolone, and azathioprine). We also note that when patients with delayed multiple REs (Table 1 ). This may be attributed to the fact that CsA does not totally block cytokine production graft function were analyzed separately, two out of five (40%) with the TNF-␣ high/IL-10 low producer geno- [26] . From our results, we suggest that CsA monotherapy post-transplant may be insufficient for blocking TNF-␣ type had multiple REs compared with 0 out of 16 (0%)
